| Autor: |
Min Woo Hwang, Jasmine Kauffeld, Sarah Belay, Joep J. de Jong, Elai Davicioni, Wenping Li, Jeanny B. Aragon-Ching |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1061-1070 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2692-3114 |
| DOI: |
10.37349/etat.2024.00274 |
| Popis: |
Upper tract urothelial cancer (UTUC) are rare subsets of urothelial cancer, which typically present with more aggressive course. Molecular markers stratifying urothelial tumors as luminal subtype and non-luminal subtype tumors have been proposed to select patients who may have greater or lesser benefit from neoadjuvant systemic therapy in bladder cancer, though not yet evaluated in UTUC. Here, a single-institution study retrospectively obtained clinical and genomic information in patients with UTUC and evaluated four patient tumors using the Decipher Bladder® assay and Foundation Medicine® test. All four patients had non-luminal molecular subtype including basal (N = 4) and mixed basal/claudin-low (N = 2) subtypes. The best clinical response achieved was stable disease in a patient who had basal/claudin-low subtype with residual ypT3 after neoadjuvant chemotherapy. For the remaining three patients, all were treated with platinum-based chemotherapy for eventual metastatic disease but all three showed progressive disease with limited overall survival, highlighting their aggressive course. The non-luminal subtype and lack of FGFR alteration may partly explain the poor overall outcomes while the real-world benefit of next generation sequencing for clinical use in UTUC patients require further clarification in a larger cohort study. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
